- Home
- SLI vs PCRX Comparison
SLI vs PCRX Comparison
Compare SLI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLI | PCRX |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | SLI | PCRX |
|---|---|---|
| Price | $5.13 | $20.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $5.25 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 2.6M | 1.0M |
| Earning Date | 11-10-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.47 |
| Revenue | N/A | ★ $716,791,000.00 |
| Revenue This Year | N/A | $6.21 |
| Revenue Next Year | N/A | $8.26 |
| P/E Ratio | ★ N/A | $42.94 |
| Revenue Growth | N/A | ★ 3.14 |
| 52 Week Low | $1.08 | $18.80 |
| 52 Week High | $6.40 | $27.64 |
Technical Indicators
Market Signals| Indicator | SLI | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 37.63 |
| Support Level | $4.75 | $18.80 |
| Resistance Level | $5.40 | $22.56 |
| Average True Range (ATR) | 0.27 | 1.41 |
| MACD | -0.03 | -0.53 |
| Stochastic Oscillator | 67.05 | 25.91 |
Price Performance
Historical ComparisonAbout SLI Standard Lithium Ltd.
Standard Lithium Corp is engaged in the exploration and development of lithium brine properties in the United States. The company is focused on the exploration and development of the Arkansas Lithium Project, which is located in south-central Arkansas. Its other projects comprise the Lanxess Project, and Bristol Dry Lake Project.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.